Printed from Voxsanity (voxsanity.com.au) — NCT05180942 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who are able to give informed consent and are willing to follow all study requirements
People aged 40 years or older
People who have been diagnosed with melanoma (of any stage) through a tissue biopsy, and who are planned to start, have started, or have already completed treatment with immune checkpoint inhibitor (a type of cancer immunotherapy) therapy
People whose medical imaging scans are of acceptable quality as judged by the study's central laboratory
People who, in the treating doctor's view, are willing to return for follow-up scans and meet all study requirements
Who may not be able to join:
People who have a known, clinically evident heart or blood vessel disease
Women who are pregnant, breastfeeding, or planning to become pregnant during the study period
People whose kidneys are not working well enough — specifically, those with a kidney filtration rate below 45 mL/min (confirm with trial site for how this is measured)
People with severe liver disease or cirrhosis (serious liver scarring)
People who have had another type of cancer (other than melanoma or common skin cancers) in the past 5 years
People whose overall health outlook suggests a life expectancy of less than 18 months, as judged by the treating doctor (for example, due to brain tumours that cannot be surgically removed)
People with another significant non-heart-related illness or condition that, in the treating doctor's opinion, would make participation unsafe or unsuitable
People with a severe allergy to iodine
People already taking part in another clinical trial that does not permit involvement in more than one trial at a time
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Principal Investigator: Stephen J Nicholls, MBBS, PhD, Monash University
Queen Elizabeth Hospital, Woodville South, South Australia
Monash Health, Clayton, Victoria
Peninsula Health, Frankston, Victoria
Cabrini Health, Malvern, Victoria
Peter MacCallum Cancer Centre, Melbourne, Victoria
Mildura Public Base Hospital, Mildura, Victoria
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT05180942
Sponsor: Monash University
Phase: Not Applicable
Status: Recruiting
Condition: Melanoma
Trial contact: +61 (0) 423245187
More information: https://clinicaltrials.gov/study/NCT05180942
Eligibility summary (AI generated)
Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who are able to give informed consent and are willing to follow all study requirements
People aged 40 years or older
People who have been diagnosed with melanoma (of any stage) through a tissue biopsy, and who are planned to start, have started, or have already completed treatment with immune checkpoint inhibitor (a type of cancer immunotherapy) therapy
People whose medical imaging scans are of acceptable quality as judged by the study's central laboratory
People who, in the treating doctor's view, are willing to return for follow-up scans and meet all study requirements
Who may not be able to join:
People who have a known, clinically evident heart or blood vessel disease
Women who are pregnant, breastfeeding, or planning to become pregnant during the study period
People whose kidneys are not working well enough — specifically, those with a kidney filtration rate below 45 mL/min (confirm with trial site for how this is measured)
People with severe liver disease or cirrhosis (serious liver scarring)
People who have had another type of cancer (other than melanoma or common skin cancers) in the past 5 years
People whose overall health outlook suggests a life expectancy of less than 18 months, as judged by the treating doctor (for example, due to brain tumours that cannot be surgically removed)
People with another significant non-heart-related illness or condition that, in the treating doctor's opinion, would make participation unsafe or unsuitable
People with a severe allergy to iodine
People already taking part in another clinical trial that does not permit involvement in more than one trial at a time
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Not Applicable
Sponsor
Monash University
Registry
ClinicalTrials.gov
Start date
7 November 2022
Est. completion
1 June 2026
Where this trial is recruiting
🇦🇺 Australia
12 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
To determine the natural history of the burden and composition of coronary atherosclerosis in individuals with melanoma treated with ICIs.
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.